0000899243-20-031172.txt : 20201116 0000899243-20-031172.hdr.sgml : 20201116 20201116194654 ACCESSION NUMBER: 0000899243-20-031172 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201112 FILED AS OF DATE: 20201116 DATE AS OF CHANGE: 20201116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sussman Joel F. CENTRAL INDEX KEY: 0001774297 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39114 FILM NUMBER: 201318965 MAIL ADDRESS: STREET 1: C/O GALERA THERAPEUTICS, INC. STREET 2: 2 W LIBERTY BLVD. #110 CITY: MALVERN STATE: PA ZIP: 19355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Galera Therapeutics, Inc. CENTRAL INDEX KEY: 0001563577 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461454898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 WEST LIBERTY BLVD #100 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 610-725-1500 MAIL ADDRESS: STREET 1: 2 WEST LIBERTY BLVD #100 CITY: MALVERN STATE: PA ZIP: 19355 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-12 0 0001563577 Galera Therapeutics, Inc. GRTX 0001774297 Sussman Joel F. C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD #100 MALVERN PA 19355 0 1 0 0 Chief Accounting Officer Common Stock 2020-11-12 4 M 0 10000 1.07 A 10000 D Common Stock 2020-11-12 4 S 0 10000 10.0627 D 0 D Common Stock 2020-11-13 4 M 0 3606 1.07 A 3606 D Common Stock 2020-11-13 4 M 0 3755 1.14 A 7361 D Common Stock 2020-11-13 4 M 0 2639 2.43 A 10000 D Common Stock 2020-11-13 4 S 0 10000 10.3197 D 0 D Stock Option (Right to Buy) 1.07 2020-11-12 4 M 0 10000 0.00 D 2023-01-22 Common Stock 10000 3606 D Stock Option (Right to Buy) 1.07 2020-11-13 4 M 0 3606 0.00 D 2023-01-22 Common Stock 3606 0 D Stock Option (Right to Buy) 1.14 2020-11-13 4 M 0 3755 0.00 D 2024-09-16 Common Stock 3755 0 D Stock Option (Right to Buy) 2.43 2020-11-13 4 M 0 2639 0.00 D 2026-03-01 Common Stock 2639 32238 D The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.00 to $10.25. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.00 to $10.75. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option has fully vested and is currently exercisable. /s/ Christopher Degnan, Attorney-in-Fact for Joel F. Sussman 2020-11-16